Back to results
US 12,590,160 B2Granted
Mitigation and reversal of intestinal fibrosis and inflammation by inhibition of TL1A function
AssigneeCedars-Sinai Medical Center
InventorsDavid Q. Shih, Stephan R. Targan, Dalin Li, Janine Bilsborough
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
Claims9
A method of reversing intestinal fibrosis in a subject having inflammatory bowel disease (IBD), comprising:
- (a) assaying and detecting a high level of connective tissue growth factor (Ctgf) in a sample obtained from the subject with intestinal fibrosis, wherein the high level of Ctgf is high as compared to a level of Ctgf in a normal individual;
- (b) administering to the subject in which the high level of Ctgf was detected in (a) a therapeutically effective dosage of one or more inhibitors of tumor necrosis factor-like cytokine 1A-death domain receptor 3 (TL1A)-(DR3) binding comprising a blocking TL1A antibody;
- and
- (c) reducing the high level of Ctgf in the subject, thereby reversing the intestinal fibrosis in the subject, wherein reversing comprises reversal of the intestinal fibrosis to a level present in the subject prior to contracting the IBD.
1 more element
Dependencies are inferred from the claim text.